

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in February 2011

WELLBUTRIN XR

1. NAME OF THE MEDICINAL PRODUCT

WELLBUTRIN XR 150mg modified release tablets.

WELLBUTRIN XR 300mg modified release tablets.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains bupropion hydrochloride 150mg or 300mg.

For excipients, see 6.1 (*List of excipients*).

3. PHARMACEUTICAL FORM

Modified release tablet.

150 mg tablet: Creamy white to pale yellow round tablet imprinted with “GS5FV” in black ink on one side and the other side plain.

300 mg tablet: Creamy white to pale yellow round tablet imprinted with “GS5YZ” in black ink on one side and the other side plain.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

WELLBUTRIN XR is indicated for the treatment of major depressive episodes.

Following satisfactory response, continuation with WELLBUTRIN XR therapy is effective in preventing relapse

4.2 Posology and method of administration

WELLBUTRIN XR tablets should be swallowed whole. The tablets should not be crushed or chewed as this may lead to an increased risk of adverse effects including seizures.

WELLBUTRIN XR tablets can be taken with or without food

Use in Adults

The recommended daily dose is 150 mg, given once daily. If no improvement is seen after 4 weeks treatment at this dose, the dose may be increased to 300 mg, given once daily. There should be an interval of at least 24 hours between successive doses.

The onset of action with bupropion has been noted as early as 14 days after starting therapy. As with all antidepressants the full antidepressant effect of WELLBUTRIN XR may not be evident until after several weeks of treatment.

Patients with depression should be treated for a sufficient period of at least 6 months to ensure that they are free from symptoms.

Insomnia is a very common adverse event which is often transient. Insomnia may be reduced by avoiding dosing at bedtime (provided there is at least 24 hours between doses)

Use in Children and Adolescents

WELLBUTRIN XR is not indicated for use in children or adolescents aged less than 18 years (see 4.4 *Special warnings and precautions for use*). The safety and efficacy of WELLBUTRIN XR in patients under 18 years of age have not been established.

Use in Elderly Patients

Efficacy has been shown equivocally in the elderly. In a clinical trial, elderly patients followed the same dose regimen as for the adults (see Use in Adults). Greater sensitivity in some elderly individuals cannot be ruled out.

Use in Patients with Hepatic Insufficiency

WELLBUTRIN XR should be used with caution in patients with hepatic impairment (see 4.4 *Special warnings and precautions for use*). Because of increased variability in the pharmacokinetics in patients with mild to moderate impairment the recommended dose in these patients is 150 mg once a day.

Use in Patients with Renal Insufficiency

The recommended dose in these patients is 150mg once a day, as bupropion and its active metabolites may accumulate in such patients to a greater extent than usual (see 4.4 *Special warnings and precautions for use*).

Discontinuing therapy

Although discontinuation reactions (measured as spontaneously reported events rather than on rating scales) were not observed in clinical studies with WELLBUTRIN XR, a tapering off period may be considered. Bupropion is a selective inhibitor of the neuronal re-uptake of catecholamines and a rebound effect or discontinuation reactions cannot be ruled out.

4.3 Contraindications

WELLBUTRIN XR is contraindicated in patients with hypersensitivity to bupropion or any of the excipients.

WELLBUTRIN XR is contraindicated in patients taking any other medicinal product containing bupropion, as the incidence of seizures is dose dependent and to avoid overdose.

WELLBUTRIN XR is contraindicated in patients with a current seizure disorder or any history of seizures.

WELLBUTRIN XR is contraindicated in patients with a known central nervous system tumour.

WELLBUTRIN XR is contraindicated in patients who, at any time during treatment, are undergoing abrupt withdrawal from alcohol or any medicinal product known to be associated with a risk of seizures on withdrawal (in particular benzodiazepines and benzodiazepine-like agents).

WELLBUTRIN XR is contraindicated for use in patients with severe hepatic cirrhosis.

WELLBUTRIN XR is contraindicated in patients with a current or previous diagnosis of bulimia or anorexia nervosa.

Concomitant use of WELLBUTRIN XR and monoamine oxidase inhibitors (MAOIs) is contraindicated. At least 14 days should elapse between discontinuation of irreversible MAOIs and initiation of treatment with WELLBUTRIN XR. For reversible MAOIs, a 24 hour period is sufficient.

4.4 Special warnings and precautions for use

Seizures

The recommended dose of modified release bupropion tablets should not be exceeded, since bupropion is associated with a dose-related risk of seizure. The overall incidence of seizure with modified release bupropion tablets in clinical trials at doses up to 450 mg/day was approximately 0.1%.

There is an increased risk of seizures occurring with the use of WELLBUTRIN XR in the presence of predisposing risk factors which lower the seizure threshold. Therefore WELLBUTRIN XR should be administered with caution to patients with one or more conditions predisposing to a lowered seizure threshold.

All patients should be assessed for predisposing risk factors, which include

- Concomitant administration of other medicinal products known to lower the seizure threshold (e.g. antipsychotics, antidepressants, antimalarials, tramadol, theophylline, systemic steroids, quinolones and sedating antihistamines)
- Alcohol abuse (see also 4.3 *Contraindications*)
- History of head trauma
- Diabetes treated with hypoglycaemics or insulin
- Use of stimulants or anorectic products

WELLBUTRIN XR should be discontinued and not recommenced in patients who experience a seizure while on treatment.

Interactions (see 4.5 *Interaction with other medicinal products and other forms of interaction*)

Due to pharmacokinetic interactions, plasma levels of bupropion or its metabolites may be altered, which may increase the potential for undesirable effects (e.g. dry mouth, insomnia, seizures). Therefore, care should be taken when bupropion is given concomitantly with medicinal products which can induce or inhibit the metabolism of bupropion.

Bupropion inhibits metabolism by cytochrome P450 2D6. Caution is advised when medicinal products metabolised by this enzyme are administered concurrently.

Neuropsychiatry

Suicide/suicidal thoughts or clinical worsening

Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored for clinical worsening (including development of new symptoms) and suicidality, especially at the beginning of a course of treatment, or at the time of dose changes, either increases or decreases. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.

Patients with a history of suicide-related events, or behaviour or thoughts, young adults, and those patients exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment.

A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.

Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.

It should be recognised that the onset of some neuropsychiatric symptoms could be related either to the underlying disease state or the drug therapy (see *Neuropsychiatric symptoms including mania and bipolar disorder below*; see 4.8 *Undesirable effects*)

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients who experience clinical worsening (including development of new symptoms) and/or the emergence of suicidal ideation/behaviour, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

Neuropsychiatric symptoms including mania and bipolar disorder

Neuropsychiatric symptoms have been reported (see 4.8 *Undesirable effects*). In particular, psychotic and manic symptomatology has been observed, mainly in patients with a known history of psychiatric illness. Additionally a major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone can increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Limited clinical data on use of bupropion in combination with mood stabilisers in patients with a history of bipolar disorder suggests a low rate of switch to mania. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.

Data in animals suggest a potential for abuse. However, studies on abuse liability in humans and extensive clinical experience show that bupropion has low abuse potential.

Clinical experience with bupropion in patients receiving ECT is limited. Caution should be exercised in patients receiving ECT therapy concomitantly with bupropion treatment.

Hypersensitivity

WELLBUTRIN XR should be discontinued promptly if patients experience hypersensitivity reactions during treatment. Clinicians should be aware that symptoms may progress or recur following the discontinuation of WELLBUTRIN XR and should ensure symptomatic treatment is administered for an adequate length of time (at least one week). Symptoms typically include skin rash, pruritus, urticaria or chest pain, but more severe reactions may include angioedema, dyspnoea/bronchospasm, anaphylactic shock, erythema multiforme or Stevens - Johnson syndrome. Arthralgia, myalgia and fever have also been reported in association with rash and other symptoms suggestive of delayed hypersensitivity (see 4.8 *Undesirable effects*). In most patients symptoms improved after stopping bupropion and initiating treatment with antihistamine or corticosteroids, and resolved over time.

Cardiovascular disease

There is limited clinical experience of the use of bupropion to treat depression in patients with cardiovascular disease. Care should be exercised if it is used in these patients. However, bupropion was generally well tolerated in studies for smoking cessation in patients with ischaemic cardiovascular disease (see 5.1 *Pharmacodynamic properties*).

Blood pressure

Bupropion has been shown not to induce significant increases in blood pressure in non-depressed patients with Stage I hypertension. However, in clinical practice, hypertension, which in some cases may be severe (see 4.8 *Undesirable effects*) and require acute treatment, has been reported in patients receiving bupropion. This has been observed in patients with and without pre-existing hypertension.

A baseline blood pressure should be obtained at the start of treatment, with subsequent monitoring especially in patients with pre-existing hypertension. Consideration should be given to discontinuation of WELLBUTRIN XR if a clinically significant increase in blood pressure is observed.

Concomitant use of bupropion and a nicotine transdermal system may result in elevations of blood pressure.

Specific patient groups

Children and adolescents (<18 years) - Treatment with antidepressants is associated with an increased risk of suicidal thinking and behaviour in children and adolescents with major depressive disorder and other psychiatric disorders.

Hepatically-impaired – Bupropion is extensively metabolised in the liver to active metabolites, which are further metabolised. No statistically significant differences in the pharmacokinetics of bupropion were observed in patients with mild to moderate hepatic cirrhosis compared with healthy volunteers, but bupropion plasma levels showed a higher variability between individual patients. Therefore WELLBUTRIN XR should be used with caution in patients with mild to moderate hepatic impairment (see section 4.2 Posology and method of administration)

All patients with hepatic impairment should be monitored closely for possible undesirable effects (e.g., insomnia, dry mouth, seizures) that could indicate high drug or metabolite levels.

Renally-impaired – Bupropion is mainly excreted into the urine as its metabolites. Therefore in patients with renal impairment, bupropion and its active metabolites may accumulate to a greater extent than usual. The patient should be closely monitored for possible undesirable effects (eg insomnia, dry mouth, seizures) that could indicate high drug or metabolite levels (see section 4.2 Posology and method of administration).

4.5 Interaction with other medicinal products and other forms of interaction

Since monoamine oxidase A and B inhibitors also enhance the catecholaminergic pathways, by a different mechanism from bupropion, concomitant use of WELLBUTRIN XR and monoamine oxidase inhibitors (MAOIs) is contraindicated (see section 4.3 *Contraindications*) as there is an increased possibility of adverse reactions from their co-administration. At least 14 days should elapse between discontinuation of irreversible MAOIs and initiation of treatment with WELLBUTRIN XR. For reversible MAOIs a 24 hour period is sufficient.

The effect of bupropion on other medicinal products

Although not metabolised by the CYP2D6 isoenzyme, bupropion and its main metabolite, hydroxybupropion inhibit the CYP2D6 pathway. Co-administration of bupropion and desipramine to healthy volunteers known to be extensive metabolisers of the CYP2D6 isoenzyme resulted in large (2-to 5-fold) increases in the C_{max} and AUC of desipramine. Inhibition of CYP2D6 was present for at least 7 days after the last dose of bupropion.

Concomitant therapy with medicinal products with narrow therapeutic indices that are predominantly metabolised by CYP2D6 should be initiated at the lower end of the dose range of the concomitant medicinal product. Such medicinal products include certain antidepressants (e.g. desipramine, imipramine), antipsychotics (e.g. risperidone, thioridazine), beta-blockers (e.g. metoprolol), serotonin selective reuptake inhibitors (SSRIs) and Type 1C antiarrhythmics (e.g. propafenone, flecainide). If WELLBUTRIN XR is added to the treatment regimen of a patient already receiving such a medicinal product, the need to decrease the dose of the original medicinal product should be considered. In these cases the expected benefit of treatment with WELLBUTRIN XR should be carefully compared with the potential risks.

Drugs which require metabolic activation by CYP2D6 in order to be effective (e.g. tamoxifen), may have reduced efficacy when administered concomitantly with inhibitors of CYP2D6 such as bupropion.

Although citalopram (a SSRI) is not primarily metabolised by CYP2D6, in one study, bupropion increased the C_{max} and AUC of citalopram by 30% and 40%, respectively.

The effect of other medicinal products on bupropion

Bupropion is metabolised to its major active metabolite hydroxybupropion primarily by the cytochrome P450 CYP2B6 (see 5.2 *Pharmacokinetic* properties). Co-administration of medicinal products that may affect the CYP2B6 isoenzyme (e.g. CYP2B6 substrates: cyclophosphamide, ifosfamide, and CYP2B6 inhibitors: orphenadrine, ticlopidine, clopidogrel) may result in increased bupropion plasma levels and lower levels of active metabolite hydroxybupropion. The clinical consequences of the inhibition of the metabolism of bupropion via CYP2B6 enzyme and the consequent changes in the bupropion-hydroxybupropion ratio are currently unknown.

Since bupropion is extensively metabolised, caution is advised when bupropion is coadministered with medicinal products known to induce metabolism (e.g. carbamazepine, phenytoin, ritonavir, efavirenz) or inhibit metabolism (e.g. valproate), as these may affect its clinical efficacy and safety.

In a series of studies in healthy volunteers, ritonavir (100 mg twice daily or 600 mg twice daily) or ritonavir 100 mg plus lopinavir 400 mg (Kaletra®) twice daily reduced the exposure of bupropion and its major metabolites in a dose dependent manner by approximately 20 to 80% (see section 5.2 *Pharmacokinetic* properties). Similarly, efavirenz 600 mg once daily for two weeks reduced the exposure of bupropion by approximately 55% in healthy volunteers. The clinical consequences of the reduced exposure are unclear, but

may include decreased efficacy in the treatment of major depression. Patients receiving any of these drugs with bupropion may need increased doses of bupropion but the maximum recommended dose of bupropion should not be exceeded.

Other interaction information

Administration of WELLBUTRIN XR to patients receiving either levodopa or amantadine concurrently should be undertaken with caution. Limited clinical data suggest a higher incidence of undesirable effects (e.g. nausea, vomiting, and neuropsychiatric events – see 4.8 *Undesirable effects*) in patients receiving bupropion concurrently with either levodopa or amantadine.

Although clinical data do not identify a pharmacokinetic interaction between bupropion and alcohol, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients drinking alcohol during bupropion treatment. The consumption of alcohol during WELLBUTRIN XR treatment should be minimised or avoided.

There have been no pharmacokinetic studies with bupropion and co-administered benzodiazepines. Based on *in vitro* metabolic pathways, there is no basis for such an interaction. After coadministration of bupropion with diazepam in healthy volunteers, there was less sedation than when diazepam was administered alone.

There has been no systematic evaluation of the combination of bupropion with antidepressants (other than desipramine and citalopram), benzodiazepines (other than diazepam), or neuroleptics. There has also been limited clinical experience with St Johns Wort.

Concomitant use of WELLBUTRIN XR and a nicotine transdermal system (NTS) may result in elevations of blood pressure.

4.6 Pregnancy and lactation

The safety of WELLBUTRIN XR for use in human pregnancy has not been established.

In a retrospective study there was no greater proportion of congenital malformations or cardiovascular malformations amongst more than thousand first trimester exposure to bupropion compared with the use of other antidepressants

Evaluation of experimental animal studies does not indicate direct or indirect harmful effects with respect to the development of the embryo or foetus, the course of gestation and peri-natal or post-natal development. Animal reproductive studies are not always predictive of the human response.

Exposure in animals was similar to the systemic exposure achieved in humans at the maximum recommended dose. The potential risk to humans is unknown. Administration of bupropion should only be considered during pregnancy if the expected benefits are greater than the potential risks. As bupropion and its metabolites are excreted in human breast milk mothers should be advised not to breast feed while taking WELLBUTRIN XR.

4.7 Effects on ability to drive and use machines

As with other CNS acting drugs bupropion may affect ability to perform tasks that require judgement or motor and cognitive skill. Patients should therefore exercise caution before driving or use of machinery until they are reasonably certain WELLBUTRIN XR does not adversely affect their performance.

4.8 Undesirable effects

The list below provides information on the undesirable effects identified from clinical experience, categorised by incidence and System Organ Class body system.

Undesirable effects are ranked under headings of frequency using the following convention; very common ($\geq 1/10$); common ($\geq 1/100$, $< 1/10$); uncommon ($\geq 1/1,000$, $< 1/100$); rare ($\geq 1/10,000$, $< 1/1,000$); very rare ($< 1/10,000$).

Immune system disorders*	Common	Hypersensitivity reactions such as urticaria.
	Very Rare	More severe hypersensitivity reactions including angioedema, dyspnoea/bronchospasm and anaphylactic shock. Arthralgia, myalgia and fever have also been reported in association with rash and other symptoms suggestive of delayed hypersensitivity. These symptoms may resemble serum sickness.
Metabolism and nutrition disorders	Common	Anorexia.
	Uncommon	Weight loss
	Very Rare	Blood glucose disturbances
Psychiatric disorders	Very common	Insomnia (see section 4.2 <i>Posology and Method of Administration</i>)
	Common	Agitation, anxiety
	Uncommon	Depression (see section 4.4 <i>Special warnings and precautions for use</i>), confusion
	Very rare	Aggression, hostility, irritability, restlessness, hallucinations, abnormal dreams including nightmares, depersonalisation, delusions, paranoid ideation
	Not known	Suicidal ideation and suicidal behaviour***
Nervous system disorders	Very Common	Headache
	Common	Tremor, dizziness, taste disorders
	Uncommon	Concentration disturbance
	Rare	Seizures (see below)**
	Very Rare	Dystonia, ataxia, Parkinsonism, incoordination, memory impairment, paraesthesia, syncope

Eye disorders	Common	Visual disturbance
Ear and labyrinth disorders	Common	Tinnitus
Cardiac disorders	Uncommon	Tachycardia
	Very Rare	Palpitations
Vascular disorders	Common	Increased blood pressure (sometimes severe), flushing
	Very Rare	Vasodilation, postural hypotension
Gastrointestinal disorders	Very Common	Dry mouth, gastrointestinal disturbance including nausea and vomiting
	Common	Abdominal pain, constipation
Hepatobiliary disorders	Very Rare	Elevated liver enzymes, jaundice, hepatitis
Skin and subcutaneous tissue disorders*	Common	Rash, pruritus, sweating.
	Very Rare	Erythema multiforme, Stevens Johnson syndrome, exacerbation of psoriasis
Musculoskeletal and connective tissue disorders	Very Rare	Twitching
Renal and urinary disorders	Very Rare	Urinary frequency and/or retention
General disorders and administration site conditions	Common	Fever, chest pain, asthenia

* Hypersensitivity may manifest as skin reactions. See “Immune system disorders” and “Skin and subcutaneous tissue disorders”.

**The incidence of seizures is approximately 0.1% (1/1,000). The most common type of seizures is generalised tonic-clonic seizures, a seizure type which can result in some cases in post-ictal confusion or memory impairment. (See 4.4 *Special warnings and precautions for use*).

***Cases of suicidal ideation and suicidal behaviour have been reported during bupropion therapy or early after treatment discontinuation. (See 4.4 *Special warnings and precautions for use*)

4.9 Overdose

Acute ingestion of doses in excess of 10 times the maximum therapeutic dose have been reported. In addition to those events reported as Undesirable Effects, overdose has resulted in symptoms including drowsiness, loss of consciousness and/or ECG changes such as conduction disturbances (including QRS prolongation), arrhythmias and tachycardia. Although most patients recovered without sequelae, deaths associated with bupropion have been reported rarely in patients ingesting large overdoses of the drug.

Treatment: In the event of overdose, hospitalisation is advised. ECG and vital signs should be monitored.

Ensure an adequate airway, oxygenation and ventilation. The use of activated charcoal is recommended. No specific antidote for bupropion is known. Further management should be as clinically indicated.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other antidepressants, ATC code: N06 AX12.

Bupropion is a selective inhibitor of the neuronal re-uptake of catecholamines (noradrenaline and dopamine) with minimal effect on the re-uptake of indolamines (serotonin) and does not inhibit either monoamine oxidase.

The mechanism of action of bupropion as an antidepressant is unknown. However, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms.

In a study in healthy volunteers, no clinically significant effect of modified release bupropion tablets (450mg/day) compared with placebo was observed on QTcF interval after 14 days of dosing to steady state.

Significant benefit was shown on the primary endpoint in 2 of 4 US studies with WELLBUTRIN XR (300-450 mg). Of the 2 positive studies, one was a placebo controlled study in patients with MDD and one was an active controlled study in patients with MDD.

In a relapse prevention study, patients responding to 8 weeks of acute treatment with open-label WELLBUTRIN SR (300 mg/day) were randomised to either WELLBUTRIN SR or placebo for a further 44 weeks. WELLBUTRIN SR demonstrated a statistically significant superiority compared to placebo ($P < 0.05$) on the primary outcome measure. The incidence of maintenance of effect during the 44 week double blind follow-up period was 64% and 48% for WELLBUTRIN SR and placebo, respectively.

5.2 Pharmacokinetic properties

Absorption

After oral administration of 300 mg bupropion hydrochloride once daily as the modified release tablet to healthy volunteers, maximum plasma concentrations (C_{max}) of approximately 160 ng/ml are observed at

approximately 5 hours. At steady state, the C_{max} and AUC values of hydroxybupropion are approximately 3 and 14 times that of bupropion, respectively. The C_{max} of threohydrobupropion at steady state is similar to that of bupropion and the AUC is approximately 5 times higher while the plasma concentrations of erythrohydrobupropion are comparable to those of bupropion. Peak plasma levels of hydroxybupropion are reached at 7 hours while those for threohydrobupropion and erythrohydrobupropion are reached at 8 hours. The AUC and C_{max} values of bupropion and its active metabolites hydroxybupropion and threohydrobupropion increase dose proportionally over a dose range of 50-200 mg following single doses and over a dose range of 300-450 mg/day following chronic dosing.

The absolute bioavailability of bupropion is not known; urinary excretion data, however, show that at least 87% of the dose of bupropion is absorbed.

The absorption of modified release bupropion tablets is not significantly affected when taken with food.

Distribution

Bupropion is widely distributed with an apparent volume of distribution of approximately 2000 L.

Bupropion, hydroxybupropion and threohydrobupropion bind moderately to plasma proteins (84%, 77% and 42%, respectively).

Bupropion and its active metabolites are excreted in human breast milk. Animal studies show that bupropion and its active metabolites pass the blood-brain barrier and the placenta. Positron Emission Tomography studies in healthy volunteers demonstrate that bupropion penetrates the CNS and binds to the striatal dopamine reuptake transporter (approximately 25% at 150 mg twice daily).

Metabolism

Bupropion is extensively metabolised in humans. Three pharmacologically active metabolites have been identified in plasma: hydroxybupropion and the amino-alcohol isomers, threohydrobupropion and erythrohydrobupropion. These may have clinical importance, as their plasma concentrations are as high or higher than those of bupropion. The active metabolites are further metabolised to inactive metabolites (some of which have not been fully characterised but may include conjugates) and excreted in the urine.

In vitro studies indicate that bupropion is metabolised to its major active metabolite hydroxybupropion primarily by the CYP2B6, while CYP1A2, 2A6, 2C9, 3A4 and 2E1 are less involved. In contrast, formation of threohydrobupropion involves carbonyl reduction but does not involve cytochrome P450 isoenzymes. (See 4.5 *Interaction with other medicinal products and other forms of interaction*)

The inhibition potential of threohydrobupropion and erythrohydrobupropion towards cytochrome P450 has not been studied.

Bupropion and hydroxybupropion are both inhibitors of the CYP2D6 isoenzyme with K_i values of 21 and 13.3 μM, respectively (see 4.5 *Interaction with other medicinal products and other forms of interaction*).

Bupropion has been shown to induce its own metabolism in animals following sub-chronic administration. In humans, there is no evidence of enzyme induction of bupropion or hydroxybupropion in volunteers or patients receiving recommended doses of bupropion hydrochloride for 10 to 45 days.

Elimination

Following oral administration of 200mg of ¹⁴C-bupropion in humans, 87% and 10% of the radioactive dose were recovered in the urine and faeces, respectively. The fraction of the dose of bupropion excreted unchanged was only 0.5%, a finding consistent with the extensive metabolism of bupropion. Less than 10% of this ¹⁴C dose was accounted for in the urine as active metabolites.

The mean apparent clearance following oral administration of bupropion hydrochloride is approximately 200 L/hr and the mean elimination half-life of bupropion is approximately 20 hours.

The elimination half-life of hydroxybupropion is approximately 20 hours. The elimination half-lives for threohydrobupropion and erythrohydrobupropion are longer (37 and 33 hours, respectively) and steady-state AUC values are 8 and 1.6 times higher than that of bupropion, respectively. Steady-state for bupropion and its metabolites is reached within 8 days.

Special Patient Groups:

Patients with renal impairment

The elimination of bupropion and its active major metabolites may be reduced in patients with impaired renal function. Limited data in patients with end-stage renal failure or moderate to severely impaired renal function indicate that exposure to bupropion and/or its metabolites was increased (see section 4.4 *Special warnings and precautions for use*).

Patients with hepatic impairment

The pharmacokinetics of bupropion and its active metabolites were not statistically significantly different in patients with mild to moderate cirrhosis when compared to healthy volunteers, although more variability was observed between individual patients. (see 4.4 *Special warnings and precautions for use*). For patients with severe hepatic cirrhosis, the bupropion C_{max} and AUC were substantially increased (mean difference approximately 70% and 3-fold, respectively) and more variable when compared to the values in healthy volunteers; the mean half-life was also longer (by approximately 40%). For hydroxybupropion, the mean C_{max} was lower (by approximately 70%), the mean AUC tended to be higher (by approximately 30%), the median T_{max} was later (by approximately 20 hrs), and the mean half-lives were longer (by approximately 4-fold) than in healthy volunteers. For threohydrobupropion and erythrohydrobupropion, the mean C_{max} tended to be lower (by approximately 30%), the mean AUC tended to be higher (by approximately 50%), the median T_{max} was later (by approximately 20 hrs), and the mean half-life was longer (by approximately 2-fold) than in healthy volunteers. (see 4.3 *Contraindications*)

Elderly patients

Pharmacokinetic studies in the elderly have shown variable results. A single dose study showed that the pharmacokinetics of bupropion and its metabolites in the elderly do not differ from those in the younger adults. Another pharmacokinetic study, single and multiple dose, has suggested that accumulation of bupropion and its metabolites may occur to a greater extent in the elderly. Clinical experience has not identified differences in tolerability between elderly and younger patients, but greater sensitivity in older patients cannot be ruled out. (see 4.4 *Special warnings and precautions for use*)

In-vitro release of bupropion with alcohol

In-vitro tests showed that at high alcohol concentrations (up to 40%), bupropion is released more rapidly from the modified release formulation (up to 20% dissolved at 2 hours) (see section 4.5 *Interaction with other medicinal products and other forms of interaction*).

5.3 Preclinical safety data

In animal experiments bupropion doses several times higher than therapeutic doses in humans caused, amongst others, the following dose-related symptoms: ataxia and convulsions in rats, general weakness, trembling and emesis in dogs and increased lethality in both species. Due to enzyme induction in animals but not in humans, systemic exposures in animals were similar to the systemic exposures seen in humans at the maximum recommended dose.

Liver changes are seen in animal studies but these reflect the action of a hepatic enzyme inducer. At recommended doses in humans, bupropion does not induce its own metabolism. This suggests that the hepatic findings in laboratory animals have only limited importance in the evaluation and risk assessment of bupropion.

Genotoxicity data indicate that bupropion is a weak bacterial mutagen, but not a mammalian mutagen, and therefore is of no concern as a human genotoxic agent. Mouse and rat studies confirm the absence of carcinogenicity in these species.

6 .Pharmaceutical particulars

6.1 List of excipients

Tablet Core:

Polyvinyl Alcohol
Glyceryl Dibehenate

Tablet Coating:

First Coating:

Ethyl Cellulose
Povidone

Macrogol

Second Coating:

Macrogol
Methacrylic Acid Ethyl Ecrylate Copolymer
Dispersion (Eudragit L30 D-55)
Silicon Dioxide
Triethyl Citrate

Printing Ink

Black Printing Ink (Opacode S-1-8090 or Opacode S-1-17805) containing E132, E110, E129 and E172.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

18 Months

6.4 Special precautions for storage

Do not store above 25°C. Keep in the original container

6.5 Nature and contents of container

White opaque high density polyethylene (HDPE) bottles containing a combination charcoal/silica gel desiccant canister and closed with a child-resistant closure that includes an induction heat seal membrane.

150mg: 7 tablets, 30 tablets and 90 tablets.

300mg: 7 tablets, 30 tablets and 90 (3x30) tablets.

6.6 Instructions for use and handling

No special requirements.

Manufacturer: Aspen Bad Oldesloe, GmbH, Germany.

License Holder and Importer: GlaxoSmithKline (Israel) Ltd, 25 Basel Petach Tikva 49002

License Number:	Wellbutrin XR 150 mg tablets	140-05-31653-00
	Wellbutrin XR 300 mg tablets	140-06-31654-00

Wel DR v2